SEC Form 6-K filed by Achilles Therapeutics plc
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2024
Commission File Number: 001-40299
Achilles Therapeutics plc
(Exact name of registrant as specified in its charter)
245 Hammersmith Road
London W6 8PW
United Kingdom
Tel: +44 (0)20 8154 4600
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Results of Annual General Meeting
On June 25, 2024, Achilles Therapeutics plc (“Achilles” or the “Company”) held its 2024 Annual General Meeting (the “Annual General Meeting”), and all resolutions were passed as proposed. At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on May 24, 2024 were duly proposed and passed on a poll.
The matters presented for a vote and the related results are as follows:
| Ordinary Resolutions | For | Against | Abstain | |||||||||
| To re-elect Edwin Moses as a Director of the Company. |
6,756,604 | 190,295 | 11,167,811 | |||||||||
| To re-elect Iraj Ali as a Director of the Company. |
6,798,071 | 150,222 | 11,166,417 | |||||||||
| To re-elect Carsten Boess as a Director of the Company. |
6,803,027 | 143,394 | 11,168,289 | |||||||||
| To re-elect Bernhard Ehmer as a Director of the Company. |
6,808,607 | 137,814 | 11,168,289 | |||||||||
| To re-elect Michael Giordano as a Director of the Company. |
6,720,495 | 142,294 | 11,251,921 | |||||||||
| To re-elect Julie O’Neill as a Director of the Company. |
6,796,562 | 149,859 | 11,168,289 | |||||||||
| To re-appoint KPMG LLP as UK statutory auditors of the Company, to hold office until the conclusion of the next Annual General Meeting. |
6,898,359 | 27,858 | 11,188,493 | |||||||||
| To authorize the Company’s Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2024. |
6,888,016 | 58,323 | 11,168,371 | |||||||||
| To receive the UK statutory annual accounts and report for the fiscal year ended 31 December 2023 and to note that the Directors do not recommend the payment of any dividend for the year ended December 31, 2023. |
6,882,217 | 56,252 | 11,176,241 | |||||||||
| To receive and approve, on a non-binding, advisory basis, the Company’s UK statutory Directors’ Remuneration Report for the year ended December 31, 2023. |
4,513,763 | 2,423,898 | 11,177,049 | |||||||||
The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to shareholders on May 24, 2024 and furnished as an exhibit to a Form 6-K filed with the U.S. Securities and Exchange Commission on May 24, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ACHILLES THERAPEUTICS PLC | ||||||
| Date: June 27, 2024 | By: | /s/ Robert Coutts | ||||
| Robert Coutts | ||||||
| Chief Financial Officer | ||||||